・Vanda shares have rallied about 62% since mid-November, erasing the stock’s losses for the year amid a series of news flows. ・Tradipitant previously failed in gastroparesis but is now under FDA ...
Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...
The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company. On ...
WASHINGTON, May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results